CA2433720A1 - Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron - Google Patents

Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron Download PDF

Info

Publication number
CA2433720A1
CA2433720A1 CA002433720A CA2433720A CA2433720A1 CA 2433720 A1 CA2433720 A1 CA 2433720A1 CA 002433720 A CA002433720 A CA 002433720A CA 2433720 A CA2433720 A CA 2433720A CA 2433720 A1 CA2433720 A1 CA 2433720A1
Authority
CA
Canada
Prior art keywords
process according
solution
ondansetron
methyl
carbazolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002433720A
Other languages
English (en)
Inventor
Ramy Lidor Hadas
Eliezer Bachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2433720A1 publication Critical patent/CA2433720A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne un procédé amélioré permettant la préparation de diméthylamino-méthyl-carbazolone et d'une base d'ondansetron, et un processus de recristallisation permettant la préparation d'un chlorhydrate dihydraté d'ondansetron pur présentant une pureté d'au moins 99,0 %.
CA002433720A 2001-01-11 2002-01-11 Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron Abandoned CA2433720A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
US60/261,052 2001-01-11
PCT/US2002/000853 WO2002055492A2 (fr) 2001-01-11 2002-01-11 Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron

Publications (1)

Publication Number Publication Date
CA2433720A1 true CA2433720A1 (fr) 2002-07-18

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002433720A Abandoned CA2433720A1 (fr) 2001-01-11 2002-01-11 Procede ameliore permettant la preparation de chlorhydrate dihydrate d'ondansetron

Country Status (21)

Country Link
EP (1) EP1355881A4 (fr)
JP (1) JP2004526692A (fr)
KR (3) KR20070054749A (fr)
CN (2) CN1496350A (fr)
AU (1) AU2002236753B2 (fr)
CA (1) CA2433720A1 (fr)
CZ (1) CZ20032090A3 (fr)
DE (1) DE02703115T1 (fr)
ES (1) ES2219201T1 (fr)
HR (1) HRP20030631A2 (fr)
HU (1) HUP0400767A2 (fr)
IL (1) IL156835A0 (fr)
IS (1) IS6869A (fr)
MX (1) MXPA03006215A (fr)
NO (1) NO20033147L (fr)
PL (1) PL368837A1 (fr)
SK (1) SK9892003A3 (fr)
TR (1) TR200401460T3 (fr)
WO (1) WO2002055492A2 (fr)
YU (1) YU56103A (fr)
ZA (1) ZA200305338B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093281A1 (fr) 2002-04-29 2003-11-13 Biogal Gyogyszergyar Rt. Methode de preparation de 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
EP1828141A4 (fr) * 2004-10-26 2009-04-01 Ipca Lab Ltd Procede monotope de preparation de l'agent antiemetique 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazol-4-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
ES2204358T1 (es) * 2000-10-30 2004-05-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.

Also Published As

Publication number Publication date
DE02703115T1 (de) 2004-10-21
MXPA03006215A (es) 2005-02-17
CN1496350A (zh) 2004-05-12
KR20030068583A (ko) 2003-08-21
EP1355881A4 (fr) 2004-03-31
NO20033147L (no) 2003-09-02
SK9892003A3 (en) 2004-05-04
KR20060113792A (ko) 2006-11-02
KR20070054749A (ko) 2007-05-29
NO20033147D0 (no) 2003-07-09
PL368837A1 (en) 2005-04-04
HRP20030631A2 (en) 2005-06-30
ZA200305338B (en) 2004-07-12
YU56103A (sh) 2006-05-25
JP2004526692A (ja) 2004-09-02
IL156835A0 (en) 2004-02-08
AU2002236753B2 (en) 2007-06-28
CZ20032090A3 (cs) 2004-08-18
IS6869A (is) 2003-07-08
WO2002055492A3 (fr) 2003-02-13
CN101045704A (zh) 2007-10-03
WO2002055492A2 (fr) 2002-07-18
EP1355881A2 (fr) 2003-10-29
HUP0400767A2 (hu) 2004-07-28
ES2219201T1 (es) 2004-12-01
TR200401460T3 (fr) 2004-08-23

Similar Documents

Publication Publication Date Title
CN101547892B (zh) 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
CN105503834B (zh) 一种伏立康唑中间体的合成方法
CA2942301A1 (fr) Synthese de clomifene au moyen d'un solvant unique
JP2004530638A (ja) 結晶性ベンラファクシン塩基、及び新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法
HU228204B1 (en) New process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and use thereof for the synthesis of tianeptine
JP2008511684A (ja) アナストロゾール中間体についての精製方法
EP3015453B1 (fr) Procédé de préparation de clomiphène
AU2002236753B2 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
KR20080000621A (ko) 항암 약물의 제조 방법
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
US20100063299A1 (en) Process for Preparing Irbesartan
TWI291956B (en) Improved process
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
US7777037B2 (en) Ziprasidone process
JP2002544184A (ja) （１ｒ，２ｓ，４ｒ）−（−）−２−［（２’−｛ｎ，ｎ−ジメチルアミノ｝−エトキシ）］−２−［フェニル］−１，７，７−トリ−［メチル］−ビシクロ［２．２．１］ヘプタン及びその薬学上許容される酸付加塩の製法
CN101883766A (zh) 制备佐米曲普坦、其盐和溶剂化物的方法
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
EP3015454A1 (fr) Forme solide stable de trans-clomiphène citrate
EP2657232A2 (fr) Processus de purification de composé de benzenesulphonamide
JP6275596B2 (ja) テルミサルタンのアンモニウム塩の製造方法
EP2072510A1 (fr) Forme cristalline d'azélastine
KR100342919B1 (ko) 트랜스체 염산 트라마돌의 분리 제조방법
WO1991017973A1 (fr) 5H-DIBENZO(a,d)CYCLOHEPTENES UTILISES COMME ANTAGONISTES DE RECEPTEURS MUSCARINIQUES
CN115028582A (zh) 一种n-芳基吡唑类药物e-52862的制备方法及其产品
EP1720867A2 (fr) Procede de preparation de ziprasidone

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued